EnterpriseWorks graduate, Revolution Medicines, tees up for oncology IND for $56M Series B Venture Capital Investment. The capital has been raised from Nextech Invest, The Column Group, and Third Rock. Current CEO, Mark Goldsmith, said, “We appreciate the strong support shown by our founding and new investors in this significant financing that will fuel the advancement of our exciting SHP2 program and innovative pipeline.”
Revolution Medicines began at the University of Illinois in 2014, founded by Professor Marty Burke. Its purpose was to develop a platform to rapidly open chemical space hereto inaccessible for drug development, while enabling Ph.D. chemist to focus on the utility of molecules rather than the synthesis of the molecules. Essentially, Revolution can attack targets that were previously considered undruggable.
Since 2014, the company has begun to focus on oncology, and the $56M will help put the SHP2 program into the clinic. The SHP2 program focuses on a molecule that blocks SHP2, a protein that regulates cellular proteins, but also acts as a driver of certain cancers and as a signaling node in various regulatory pathways.
Revolution will continue with its discovery and research and expects to test its SHP2 drug as a monotherapy and in combination with other treatments for patients with advanced cancers.
“The raise of new capital, expansion of our executive team and board with seasoned leaders, and multiple presentations about progress in our SHP2 program at the recent AACR conference all reflects enormous momentum in our effort to outsmart cancer,” said Goldsmith.
Read the full story here.